Spotlight On... Philips preps for billion-dollar deals in wake of Lighting IPO; Stentys' stent for long coronary lesions gets CE mark; FDA clears Astute Medical's improved NephroCheck Test; and more...
Royal Philips ($PHG) has started making noises as if all that cash from its recent IPO for its Lighting business is already burning a hole in its pocket. The company's CEO Frans van Houten told Bloomberg that Philips is looking to make more acquisitions along the lines of its $1.2 billion buy of catheter-based visualization and treatment player Volcano, as well as smaller deals. More
Stentys nabbed a CE mark for the longest version of its Xposition stent for coronary lesions. Release
The FDA cleared some improvements to Astute Medical's NephroCheck Test Kit that will extend the product's shelf life. Release
NeuroMetrix ($NURO) closed a $21.3 million private placement of preferred stock and warrants and used $13.8 million to redeem outstanding preferred stock. Release
Summary
Royal Philips ($PHG) has started making noises as if all that cash from its recent IPO for its Lighting business is already burning a hole in its pocket. The company's CEO Frans van Houten told...